a*********e
发帖数: 100 | |
a*********e
发帖数: 100 | |
N**********p
发帖数: 408 | 3 为什么是ARNA，而不是OREX和VVUS
【在 a*********e 的大作中提到】
: 先进一点@8.18
|
a*********e
发帖数: 100 | 4 纯TA.
【在 N**********p 的大作中提到】
: 为什么是ARNA，而不是OREX和VVUS
|
N**********p
发帖数: 408 | 5 February 25th is the day that Vivus (VVUS) will offer its Q4 quarterly
conference call. There will be a lot of ears listening to the call, but many
of them will not even have an investment in Vivus. Others that will be
paying close attention are investors in Arena (ARNA) and Orexigen (OREX).
Vivus, Arena and Orexigen all are vying for a position in the prescription
anti-obesity market, and while the three companies are at different stages,
the results offered by Vivus could be telling in what to expect moving
forward.
http://seekingalpha.com/article/1215041-vivus-arena-and-orexige
【在 a*********e 的大作中提到】
: 纯TA.
|
b*****p
发帖数: 9649 | 6 这篇文章有意思！很受启发，谢谢！
many
,
【在 N**********p 的大作中提到】
: February 25th is the day that Vivus (VVUS) will offer its Q4 quarterly
: conference call. There will be a lot of ears listening to the call, but many
: of them will not even have an investment in Vivus. Others that will be
: paying close attention are investors in Arena (ARNA) and Orexigen (OREX).
: Vivus, Arena and Orexigen all are vying for a position in the prescription
: anti-obesity market, and while the three companies are at different stages,
: the results offered by Vivus could be telling in what to expect moving
: forward.
: http://seekingalpha.com/article/1215041-vivus-arena-and-orexige
|
N**********p
发帖数: 408 | 7 呵呵，就看周一盘后了。
【在 b*****p 的大作中提到】
: 这篇文章有意思！很受启发，谢谢！
:
: many
: ,
|
X*********r
发帖数: 11803 | 8 正的假的
★ 发自iPhone App: ChineseWeb 7.8
【在 a*********e 的大作中提到】
: 先进一点@8.18
|
a*********e
发帖数: 100 | |
N**********p
发帖数: 408 | 10 开跌了，估计盘后的消息不太好
【在 a*********e 的大作中提到】
: 接着涨。
|
t******s
发帖数: 378 | |
